{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04111484: Not Applicable Interventional Completed Headache, Migraine
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tabituximab barzuxetan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04286438: Phase 3 Interventional Completed Hemorrhage
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tabituximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rolinsatamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04278924: Phase 2 Interventional Completed Primary Immune Thrombocytopenia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04462536: Phase 3 Interventional Completed Stroke, Acute
(2020)
Source URL:
Class:
PROTEIN
TAT-NR2B9C is a synthetic peptide fusion of the nine C-terminal residues of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor and the cell membrane protein transduction domain of the HIV-1 tat protein. It is a postsynaptic density protein-95 (PSD95) inhibitor with neuroprotective properties. It is under development for the treatment of acute stroke and acute cerebral ischemia.
Status:
Investigational
Source:
NCT03754309: Phase 2 Interventional Completed Dermatitis, Atopic
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02330445: Phase 1/Phase 2 Interventional Completed Arthritis, Rheumatoid
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ispectamab debotansine [INN]
Source URL:
Class:
PROTEIN
